Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | MPO | P05164 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6680826 | 0.90 | SIGMAR1 (0.55) | MPOSIGMAR1BCHE | |
| SCHEMBL6680346 | 0.87 | GAA (0.55) | GAAMAPTMPOTP53THRB | |
| SCHEMBL6682815 | 0.84 | TP53 (0.64) | GAAMAPTTP53THRBMEN1 | |
| SCHEMBL1785986 | 0.82 | KDM4E (0.51) | MPO | |
| SCHEMBL12607392 | 0.78 | LMNA (0.46) | MAPTMEN1KMT2ALMNA | |
| SCHEMBL10863420 | 0.75 | MAOB (0.40) | GAAMEN1KMT2ATDP1EPHX2 | |
| SCHEMBL27228 | 0.73 | GAA (0.95) | GAAMAPTMPOSIGMAR1MEN1 | |
| SCHEMBL25432637 | 0.72 | GAA (0.91) | GAAMAPTMPOSIGMAR1MEN1 | |
| Hydrochloric Acid SCHEMBL1983401 | 0.72 | GAA (1.00) | GAAMAPTMPOSIGMAR1MEN1 | |
| Ammonia Solution, Strong SCHEMBL23581968 | 0.72 | GAA (0.91) | GAAMAPTMPOSIGMAR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6831068-B2 | Containing a 10,13-dioxa-15,18-diazatricyclo(10.6.2.015,20)-icos-1(18)- en-5-yl 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranoside group | ABBOTT LABORATORIES | 2004-12-14 | — | — | US | disclosed |
| EP-1474431-A2 | MACROLIDE ANTIBACTERIAL COMPOUNDS | Abbott Laboratories (US) | 2004-11-10 | — | — | EP | disclosed |
| US-20040009931-A1 | Macrolide antibacterial compounds | ABBVIE INC. | 2004-01-15 | — | — | US | disclosed |
| US-20030171308-A1 | Macrolide antibacterial compounds | ABBOTT LABORATORIES | 2003-09-11 | — | — | US | disclosed |
| WO-2003068790-A2 | MACROLIDE ANTIBACTERIAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009931-A1 | Macrolide antibacterial compounds | MRPL21, RPN1, CASP1 | GAA 261/4885MAPT 4610/4885MPO 64/4885 |
| US-20030171308-A1 | Macrolide antibacterial compounds | RPN1, MRPL21, CASP1 | GAA 273/4885MAPT 4628/4885MPO 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.